Ian Somaiya

Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH)'s Ignite3 trial evaluating the company's lead drug candidate eravacycline for treating complicated urinary tract infections, or cUTIs, failed to ace a late-stage trial. At last check, the shares were plunging nearly 61 percent to $2.12....

The performance of the tardive dyskinesia drug Ingrezza had sell-side analysts gushing over Neurocrine Biosciences, Inc. (NASDAQ: NBIX)'s third-quarter results. Given the buoyancy surrounding Ingrezza, analysts scrambled to designate Neurocrine as their top mid-cap pick. Ingrezza...

BMO Capital's Ian Somaiya decreased his price target for Amgen, Inc. (NASDAQ: AMGN) from $198 to $192 while maintaining his Market Perform rating in an analyst note Thursday. The company reported $5.43 billion in third-quarter sales Wednesday after the market close, which came in below BMO Capital'...

BMO Capital Markets isn't calling the bottom on Biogen Inc (NASDAQ: BIIB) despite the risk to its MS franchise and Spinraza getting priced in. With Biogen's MS franchise thesis playing out, BMO upgraded shares of the company from Market Perform to Outperform and lowered its price target...

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) lost around one quarter of their value Thursday and another 7 percent early Friday morning in reaction to a concerning U.S. Food and Drug Administration letter sent to doctors regarding its liver treatment product called Ocaliva for the...

BMO Capital Markets said in a note CHS-3351 may be Coherus Biosciences Inc (NASDAQ: CHRS)'s most underappreciated asset. CHS-3351 is a biosimilar of ranibizumab, an mAb fragment against VEGF-A used to treat neovascular age-related macular degeneration, or AMD. Promising Potential Analyst Ian...

BMO Capital Markets' M. Ian Somaiya maintained a Market Perform rating on Gilead Sciences, Inc. (NASDAQ: GILD) with a price target boosted from $75 to $76 after the company reported its first quarter results. Gilead's reported revenues of $6.5 billion fell short of the $6.66 billion...

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced that Soliris has failed to meet primary endpoints in a Phase II/III study related to the prevention of delayed graft function in adult recipients of diseased-donor kidney transplants who have elevated risk of disease. Soliris failed to achieve...

Ra Pharmaceuticals Inc (NASDAQ: RARX)'s lead drug, RA101495, could take about 15 percent of the refractory MG (Myasthenia Gravis) market, given the convenience of a daily subcutaneous administration, BMO Capital Markets’ Ian Somaiya said in a report. He initiated coverage of Ra Pharma with an...

BMO says the upcoming clinical data's offer possible trading opportunity in Biogen Inc (NASDAQ: BIIB) shares. The market is expecting Phase III Sola data and aducanumab titration data, both in December. Last month, FDA granted fast track status for aducanumab, Biogen's investigational...

Following the release of clinical data from Celgene Corporation (NASDAQ: CELG)'s CELMoD pipeline, BMO Capital Markets said it believes near-term impact on the company's shares may be limited. However, the firm believes the pipeline optionality from 2020–2030 to be meaningful. The firm's lead...